Author: Barkoff, Courtney M.; Mousa, Shaker A.
Title: Pharmacotherapy in COVID 19: Potential Impact of Targeting the Complement System Cord-id: f6t0fkez Document date: 2020_12_24
ID: f6t0fkez
Snippet: Coronavirus disease 2019 (COVID-19), a respiratory illness caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has claimed over one million lives worldwide since December 2019. The complement system, while a first-line immune defense against invading pathogens, has off-target effects that lead to increases in inflammation, tissue damage, and thrombosis; these are common, life-threatening complications seen in patients with COVID-19. This review explores the pot
Document: Coronavirus disease 2019 (COVID-19), a respiratory illness caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has claimed over one million lives worldwide since December 2019. The complement system, while a first-line immune defense against invading pathogens, has off-target effects that lead to increases in inflammation, tissue damage, and thrombosis; these are common, life-threatening complications seen in patients with COVID-19. This review explores the potential impact of complement activation in COVID-19 and possible treatments targeting the complement system.
Search related documents:
Co phrase search for related documents- access program and low mortality: 1, 2
- access program and lung function: 1
- access program and lung injury: 1, 2
- access program and lymphocyte count: 1
- activation site and acute lung injury: 1
- activation site and lung injury: 1, 2
Co phrase search for related documents, hyperlinks ordered by date